Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom
Covered in this story
What has happened since
- Nvidia is down 6.0% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Nvidia
- Truist Securities: $228 → $346 by Aug 2027 · Buy via Investing.com
- UBS: $228 → $300 by Aug 2027 · Buy via Investing.com
- Raymond James: $228 → $515 by Aug 2027 · Strong Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $NVDA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Nvidia →Dalsna Finance is currently tracking 70 stories mentioning Nvidia, the earliest published 19 May 2026.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.